India I Equities

Consumer

Visit Note

1 July 2014

Bajaj Corp.

Unblemished growth; Buy

Key takeaways from management meet

Inventory correction to cause volume drop. Management indicated that inventory in the trade remains in the correction mode (from 45 days of sales in to 32 days by end of Mar'14). This is primarily owing to continued slowdown in rural as well as urban sales. As per management, volumes in rural areas may drop further due to delayed and deficient monsoon.

Price hikes to aid brand building activities. Prices of glass and light liquid paraffin (both key inputs), have increased 5% and ~8% respectively. Consequently, the company hiked prices by 5% in April 14. The management indicated that in case of any gross margin expansion, it will invest the savings into brand-building activities.

Re-structuring of 'No Marks' almost over. The company has restructured the portfolio of 'No Marks'. It has reduced the number of SKUs from 53 to 19, which will help reduce investment in its inventory. Also, it has appointed two new contract manufacturers which will streamline the supply chain. The company has also increased the distribution of No Marks from 167,000 outlets to 300,000 outlets; it intends to raise it further to 600,000 outlets by Mar 15. We expect the benefits of restructuring of No Marks to be visible in 2HFY15 and FY16.

Our take. Competition in almond-based hair oils is benign. Dabur's Almond Hair Oil has failed to gain more than 4% market share. Also, Keo Karpin is not investing in pushing its brands. This has led to Bajaj Corp. gaining market share. The market-share ratio of Bajaj Corp. to Keo Karpin has risen from 4.34 to 4.44. We expect 13% earnings CAGR for the company in FY14-16. We value the stock at target price of ₹270, at PE of 18x FY16e earnings. Also, we expect the success of Kailash Parbat and No Marks-acquisition to reduce dependence on Bajaj Almond Drops, erasing the 'single-product-company' tag. Risks. Further increase in input rises and keener competition.


FY12	FY13	FY14e	FY15e	FY16e
4,722	6,057	6,707	7,704	8,780
1,201	1,662	1,719	1,931	2,206
8.1	11.3	11.7	13.1	15.0
21.2	38.4	3.5	12.3	14.2
28.6	20.7	20.0	17.8	15.6
8.0	7.1	6.6	6.2	5.3
29.8	36.4	34.3	35.9	36.8
28.0	36.7	36.0	38.3	39.1
1.9	3.0	3.0	3.3	3.5
(79.2)	(76.9)	(55.0)	(60.9)	(62.1)
	4,722 1,201 8.1 21.2 28.6 8.0 29.8 28.0 1.9	4,722 6,057 1,201 1,662 8.1 11.3 21.2 38.4 28.6 20.7 8.0 7.1 29.8 36.4 28.0 36.7 1.9 3.0	4,722 6,057 6,707 1,201 1,662 1,719 8.1 11.3 11.7 21.2 38.4 3.5 28.6 20.7 20.0 8.0 7.1 6.6 29.8 36.4 34.3 28.0 36.7 36.0 1.9 3.0 3.0	4,722 6,057 6,707 7,704 1,201 1,662 1,719 1,931 8.1 11.3 11.7 13.1 21.2 38.4 3.5 12.3 28.6 20.7 20.0 17.8 8.0 7.1 6.6 6.2 29.8 36.4 34.3 35.9 28.0 36.7 36.0 38.3 1.9 3.0 3.0 3.3

Rating: Buy

Target Price: ₹270 Share Price: ₹233

Key data	BJCOR IN / BACO.BO
52-week high / low	₹287 / ₹198
Sensex / Nifty	25414 / 7611
3-m average volume	US\$0.5m
Market cap	₹34bn / US\$573m
Shares outstanding	148m

Shareholding pattern (%)	Mar '14	Dec '13	Mar '13
Promoters	75.0	75.0	75.0
- of which, Pledged	0.0	0.0	0.0
Free Float	25.0	25.0	25.0
- Foreign Institutions	13.5	12.9	13.3
- Domestic Institutions	1.9	2.1	2.3
- Public	9.6	10.0	9.4



Source: Bloomberg

Aniruddha Joshi

+9122 6626 6732 Aniruddhajoshi1@rathi.com

Shilpi Taparia

shilpitaparia@rathi.com

Head of Research
Shirish Pardeshi
+9122 6626 6730

shirishpardeshi@rathi.com

Anand Rathi Shares and Stock Brokers Limited (hereinafter "ARSSBL") is a full service brokerage and equities research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient and is to be circulated only within India and to no countries outside India. Disclosures and analyst certifications are present in Appendix.

Anand Rathi Research India Equities

Quick Glance – Financials and Valuations

Fig 1 – Income statement (₹ m)						
Year-end: Mar	FY12	FY13	FY14e	FY15e	FY16e	
Net sales	4,722	6,057	6,707	7,704	8,780	
Sales growth (%)	31.7	28.3	10.7	14.9	14.0	
- Op. expenses	3,568	4,342	4,857	5,578	6,357	
EBIDTA	1,154	1,715	1,849	2,126	2,423	
EBITDA margins (%)	24.4	28.3	27.6	27.6	27.6	
- Interest	1	1	59	-	-	
- Depreciation	26	40	43	67	77	
+ Other income	385	411	412	354	411	
- Tax	311	424	440	483	551	
Income tax rate	20.6	20.3	20.4	20.0	20.0	
PAT	1,201	1,662	1,719	1,931	2,206	
Extra Ordinary Items	-	-	(230.0)	(376.0)	(43.2)	
Minority Interest	-	-	-	-	-	
Consolidated PAT	1,201	1,662	1,489	1,555	2,163	
FDEPS (₹/share)	8.1	11.3	11.7	13.1	15.0	
FDEPS Growth	21.2	38.4	3.5	12.3	14.2	
Source: Company, Anand Ra	athi Research					

Year-end: Mar	EV40	FY13	EV14a	FY15e	FY16e
	FY12		FY14e		
Share capital	148	148	148	148	148
Reserves & surplus	4,131	4,678	5,045	5,402	6,282
Shareholders' fund	4,278	4,826	5,192	5,550	6,429
Minority interests	-	-	-	-	-
Debt	4	-	-	-	-
Def Tax Liability	10	15	4	4	4
Capital employed	4,292	4,840	5,196	5,553	6,433
Fixed assets	819	1,221	2,366	2,223	2,503
Investments	3,135	1,845	1,575	2,275	2,975
Of Which liquid	3,135	1,845	1,575	2,275	2,975
Working capital	64	(118)	(37)	(58)	(69)
Cash	275	1,892	1,292	1,114	1,025
Capital deployed	4,292	4,840	5,196	5,553	6,433
Net Debt	(3,405)	(3,737)	(2,867)	(3,389)	(4,000)
W C turn (%)	1.4	(1.9)	(0.5)	(8.0)	(0.8)
Book Value (₹/Sh)	29.1	32.8	35.2	37.7	43.6


Fig 3 – Cash-flow statement (₹ m)						
Year-end: Mar	FY12	FY13	FY14e	FY15e	FY16e	
Consolidated PAT	1,201	1,662	1,489	1,555	2,163	
+Depreciation	26	40	43	67	77	
Cash profit	1,198	1,700	1,533	1,997	2,283	
- Incr/(Decr) in WC	28	(157)	(81)	22	11	
Operating cash flow	1,226	1,544	1,452	2,019	2,294	
-Capex	(196)	1,188	(1,188)	(300)	(400)	
Free cash flow	1,030	2,731	264	1,719	1,894	
-Dividend	(1,013)	(1,114)	(1,133)	(1,198)	(1,283)	
+ Equity raised	-	-	-	-	-	
+ Debt raised	-	-	-	-	-	
-Investments	(556)	-	270	(700)	(700)	
-Misc. items	-	-	-	-	-	
Net cash flow	(539)	1,617	(600)	(178)	(89)	
+Opening cash	813	275	1,892	1,292	1,114	
Closing cash	275	1,892	1,292	1,114	1,025	
Source: Company, Anand F	Rathi Research					

Fig 4 – Ratio analys	_		=144	=1/4=	=1//0
Year-end: Mar	FY12	FY13	FY14e	FY15e	FY16e
P/E (x)	28.6	20.7	20.0	17.8	15.6
P/B (x)	8.0	7.1	6.6	6.2	5.3
EV/Sales (x)	6.7	5.2	4.7	4.1	3.6
EV/EBITDA (x)	27.3	18.4	17.0	14.8	13.0
RoAE (%)	29.8	36.4	34.3	35.9	36.8
RoACE (%)	28.0	36.7	36.0	38.3	39.1
Dividend yield (%)	1.9	3.0	3.0	3.3	3.5
Dividend payout (%)	49.1	57.7	55.8	53.5	50.1
RM to sales (%)	46.6	42.5	40.1	40.0	40.0
Ad spend to sales (%)	22.5	22.8	25.8	25.8	25.8
EBITDA growth (%)	6.8	48.6	7.8	15.0	14.0
EPS growth (%)	21.2	38.4	3.5	12.3	14.2
PAT margin (%)	27.6	25.4	27.4	25.6	25.1
FCF /EPS (%)	85.8	164.4	15.3	89.0	85.9
OCF/Sales (%)	26.0	25.5	21.6	26.2	26.1
Source: Company, Anand Rat	thi Research				

Fig 5 – PE band







Source: Company


Anand Rathi Research 2

Appendix

Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Important Disclosures on subject companies Rating and Target Price History (as of 30 June 2014)



The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues

Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps (>US\$1bn) and Mid/Small Caps (<US\$1bn) as described in the Ratings Table below:

Ratings Guide				
· ·	Buy	Hold	Sell	
Large Caps (>US\$1bn)	>15%	5-15%	<5%	
Mid/Small Caps (<us\$1bn)< td=""><td>>25%</td><td>5-25%</td><td><5%</td><td></td></us\$1bn)<>	>25%	5-25%	<5%	
Anand Rathi Research Ratings Distribution	(as of 30 June 2014)			
Amana Hami Hoodardii Hamiyo Didhibadidii	Buy	Hold	Sell	
Anand Rathi Research stock coverage (182)	61%	27%	12%	
% who are investment banking clients	5%	0%	0%	

Other Disclosures

This report has been issued by ARSSBL which is a SEBI regulated entity, and which is in full compliance with all rules and regulations as are applicable to its functioning and governance. The investors should note that ARSSBL is one of the companies comprising within ANAND RATHI group, and ANAND RATHI as a group consists of various companies which may include (but is not limited to) its subsidiaries, its affiliates, its group companies who may hold positions, views, stakes and may service the companies covered in this report independent of ARSSBL. Investors are cautioned to be aware that there could arise a potential conflict of interest in the views held by ARSSBL and other companies of Anand Rathi who maybe affiliated, connected or catering to the companies mentioned in the Research Report; even though, ARSSBL and Anand Rathi are fully complaint with all procedural and operational regulatory requirements. Thus, investors should not use this as a sole basis for making their investment decision and should consider the recommendations mentioned in the Research Report bearing in mind the aforementioned.

Further, the information herein has been obtained from various sources which we believe is reliable, and we do not guarantee its accuracy or completeness. Neither the information nor any opinion expressed herein constitutes an offer, or an invitation to make an offer, to buy or sell any securities or any options, futures or other derivatives related to such securities (hereinafter referred to as "Felated Investments"). ARSSBL and/or Anand Rathi may trade for their own accounts as market maker / jobber and/or arbitrageur in any securities of the companies mentioned in the Research Report or in related investments, and may be on taking a different position from the ones which haven been taken by the public orders. ARSSBL and/or Anand Rathi and its affiliates, directors, officers, and employees may have a long or short position in any securities of the companies mentioned in the Research Report or in Related Investments. ARSSBL and/or Anand Rathi, may from time to time, perform investment banking, investment management, financial advisory or any other services not explicitly mentioned herein, or solicit investment banking or other business from, any entity and/or company mentioned in this Research Report; however, the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the other companies of Anand Rathi, even though there might exist an inherent conflict of interest.

Furthermore, this Research Report is prepared for private circulation and use only. It does not have regard to the specific investment objectives, financial situation and the specific financial needs or objectives of any specific person who may receive this Research Report. Investors should seek financial advice regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in this Research Report, and, should understand that statements regarding future prospects may or may not be realized, and we can not guarantee the same as analysis and valuation is a tool to enable investors to make investment decisions but, is not an exact and/or a precise science. Investors should note that income from such securities, if any, may fluctuate and that each security's price or value may rise or fall. Past performance is not necessarily a guide to future performance. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related investments mentioned in this report.

Other Disclosures pertaining to distribution of research in the United States of America

This material was produced by ARSSBL, solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. It is distributed in the United States of America by Enclave Capital LLC (19 West 44th Street, Suite 1700, New York, NY 10036) and elsewhere in the world by ARSSBL or an authorized affiliate of ARSSBL (such entities and any other entity, directly or indirectly, controlled by ARSSBL, the "Affiliates"). This document does not constitute an offer of, or an invitation by or on behalf of ARSSBL or its Affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which ARSSBL or its Affiliates consider to be reliable. None of ARSSBL or its Affiliates accepts any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significantly variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.

- 1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
- 2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- 3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- 4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
- 5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
- 6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

Enclave Capital LLC is distributing this document in the United States of America. ARSSBL accepts responsibility for its contents. Any US customer wishing to effect transactions in any securities referred to herein or options thereon should do so only by contacting a representative of Enclave Capital LLC.

© 2014 Anand Rathi Shares and Stock Brokers Limited. All rights reserved. This report or any portion thereof may not be reprinted, sold or redistributed without the prior written consent of Anand Rathi Shares and Stock Brokers Limited.

Additional information on recommended securities/instruments is available on request.